<DOC>
	<DOCNO>NCT00254397</DOCNO>
	<brief_summary>The goal clinical research study learn drug leuprolide increase level immune cell body . Researchers also want know drug give together melanoma vaccine ( gp100 MAGE-3 ) improve ability tumor fight immune cell ( T cell ) fight melanoma cell . Primary Objective : 1 . To compare tumor-specific immune response melanoma-specific peptide vaccine , gp100 MAGE-3 presence absence luteinizing hormone-releasing hormone ( LHRH ) agonist-Leuprolide , patient stage IIb III melanoma , uveal melanoma stage IV melanoma metastatic lesion ( ) surgically remove . Secondary Objectives : 1 . To evaluate kinetics enhanced thymic activity measure TREC analysis flow cytometric analysis follow sex hormone ablation Leuprolide melanoma patient . 2 . To assess whether significant difference overall quality life ( QOL ) patient receive Leuprolide receive leuprolide .</brief_summary>
	<brief_title>Melanoma Vaccine With Peptides Leuprolide</brief_title>
	<detailed_description>This study use vaccine name gp100 MAGE-3 immunize patient melanoma . The type melanoma use contains protein also find vaccine . These vaccine design stimulate immune cell , also call T cell , recognize kill melanoma cell . Leuprolide study determine whether ( design ) improve response vaccine . If eligible treatment , assign one two group either receive one vaccine two different vaccine , depend tissue type ( either gp100 vaccine alone gp100 MAGE-3 vaccine ) . A small amount vaccine ( ) inject skin test body 's immune response vaccine . The size skin reaction measure 48-72 hour . This skin test do receive vaccine , 6 month , 12 month , possible.The participant and/or participant 's family give detailed verbal write instruction measure reaction skin test . A data sheet ruler ( cm/mm ) give participant . You randomly assign ( toss coin ) one 2 treatment group . Participants one group receive leuprolide vaccine ( ) . Participants group receive leuprolide . Which group assign depend partially age . If assign receive leuprolide injection , also bone mineral density test check strength bone . Before treatment start , ask answer questionnaire quality life sexual functioning . Then 3 month 12 month treatment , ask answer questionnaire . It take 20 minute time finish questionnaire . The vaccine inject skin every 3 week total 48 week . Those patient Group I receive 32 injection peptide , whereas patient Group II receive 64 injection peptide 48 week period . If assign receive leuprolide , leuprolide injected muscle begin study 12 week , total 2 additional injection . Both vaccine leuprolide injection give time melanoma outpatient clinic M. D. Anderson . Blood ( 4 teaspoon ) take 6 week , 12 week , every 12 week 48 week , time tumor start grow back . Researchers use blood find well immune cell work fight tumor cell . At around 24 week 48 week treatment , CT scan chest , abdomen pelvis check status disease . At around 24 week , receive leuprolide abnormal bone mineral density test treatment , also second bone mineral density test check strength bone . You may take study disease get bad intolerable side effect occur . If take study , ask repeat scan physical exam , include blood ( 4 tablespoon ) routine test . Following first 48 week treatment period , evaluate every 3 month one year , every 4 month one year , every 6 month one year , year clinically feasible . You MRI/CT brain , chest , abdomen pelvis check status disease . If disease get bad intolerable side effect occur , take study . Blood ( 4 tablespoon ) draw routine lab test . An additional 4 tablespoon blood draw follow-up visit determine long t-cell count remain high . This investigational study . Gp100 MAGE-3 vaccine experimental authorize research use . Leuprolide approve treat prostate cancer patient gynecological disease , approve treatment melanoma . Up 100 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . HLAA *0201 positive 2 . Patients &gt; /= 18 year old histologically document diagnosis stage IIbIV melanomas clinically render free disease surgery 3 . Uveal melanoma patient follow definitive treatment radiation therapy and/or enucleation . 4 . Karnofsky Performance Scale &gt; /= 60 % . 5 . White Blood Count ( WBC ) &gt; /= 3000/mm^3 . 6 . Platelet count &gt; /= 90,000mm^3 . 7 . Serum creatinine &lt; /= 2.0mg/dl . 8 . Serum alanine aminotransferase ( ALT ) &lt; /= 3 time upper limit normal ( ULN ) ) 9 . Total bilirubin equal less 2 time upper limit normal ( ULN ) ) , except patient Gilbert 's syndrome must total bilirubin less 3.0mg/dl . 10 . Seronegative HIV antibody . ( The experimental treatment evaluate protocol depends intact immune system . Patients HIV seropositive decrease immune competence thus less responsive experimental treatment susceptible toxicity . ) 11 . Negative pregnancy test serum urine bHCG test woman menstruation past 12 month without sterilization surgery . 12 . Unless surgically sterile bilateral tuballigation vasectomy partner ( ) , subject agrees continue use barrier method contraception throughout study : condom , diaphragm , sponge plus spermicide . Abstinence acceptable form birth control . 1 . Prior systemic therapy ( include immunomodulate agent ) , radiation surgery require general anesthesia melanoma within 28 day start study treatment . 2 . Autoimmune diseases . 3 . Concurrent systemic inhale steroid therapy . 4 . Any form active primary secondary immunodeficiency . 5 . History immunization gp100 MAGE3 . 6 . Prior malignancy except follow : adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , surgically treated Stage I II cancer patient currently complete remission ( least 5 year ) , cancer patient diseasefree 5 year . 7 . Received Luteinizing hormonereleasing hormone ( LHRH ) agonist within past 5 year . 8 . Use oral contraceptive , hormone replacement therapy androgen preparation . 9 . Hypersensitivity gonadotropinreleasing hormone analogue . 10 . Active systemic infection require intravenous antibiotic . 11 . Lactating woman woman plan lactation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Uveal Melanoma</keyword>
	<keyword>Peptide Vaccine</keyword>
	<keyword>LHRH-agonist</keyword>
	<keyword>Leuprolide</keyword>
	<keyword>Lupron</keyword>
	<keyword>MAGE-3 Peptide</keyword>
	<keyword>MAGE-3</keyword>
	<keyword>GP100 Peptide</keyword>
	<keyword>Melanoma vaccine</keyword>
	<keyword>Tumor fight immune cell</keyword>
	<keyword>T cell</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Eye Cancer</keyword>
</DOC>